Stocktoria

Arcutis Biotherapeutics, Inc. ARQT

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-01-31

Arcutis Biotherapeutics, Inc. statistics & valuation

Market cap$3.4B
P / S9.0×
P / B17.8×
Net margin-4.3%
Return on equity-8.5%
FCF margin-1.7%
Net debt$66.1M
Enterprise value USD$3.4B
Earnings yield EBIT/EV-0.4%
Return on capital-4%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-8449.80% -439.80% -71.30% -4.30% 2019202020212022202320242025
Gross margin (%)
2019202020212022202320242025
Operating margin (%)
-8183.00% -404.50% -65.30% -3.30% 2019202020212022202320242025
Return on equity (%)
-50.10% -69.30% -148.60% -295.60% -88.90% -8.50% 2019202020212022202320242025
Shares outstanding
2.1M 43.3M 50.3M 61.0M 96.8M 121.0M 127.2M 2019202020212022202320242025
Net debt ($)
-$65.1M -$24.1M $144.1M $113.4M $35.9M $66.1M 2019202020212022202320242025
Share buybacks ($)
2019202020212022202320242025
Return on assets (%)
-39.20% -45.50% -50.60% -69.30% -76.80% -40.10% -3.70% 2019202020212022202320242025
Free cash flow margin (%)
-7000.80% -415.20% -57.10% -1.70% 2019202020212022202320242025
Debt / equity (×)
0.00× 0.24× 0.94× 2.28× 0.68× 0.58× 2019202020212022202320242025
EPS ($)
-$22.78 -$3.80 -$4.18 -$5.66 -$3.78 -$1.16 -$0.13 2019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin-3.3%-65.3%-404.5%-8183.0%———
Net margin-4.3%-71.3%-439.8%-8449.8%———
FCF margin-1.7%-57.1%-415.2%-7000.8%———
Return on assets-3.7%-40.1%-76.8%-69.3%-50.6%-45.5%-39.2%
Return on equity-8.5%-88.9%-295.6%-148.6%-69.3%-50.1%64.6%
Debt / equity0.58×0.68×2.28×0.94×0.24×0.00×—
Current ratio3.174.157.0811.5712.0912.9620.33

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.